Pharmaceuticals company Neuland Laboratories announced Q2FY26 results Total Income: Rs 516.1 crore compared to Rs 315.2 crore during Q2FY25, change 63.70%. EBITDA: Rs 156.9 crore compared to Rs 65.7 crore during Q2FY25, change 138.80%. EBITDA Margin: 30.40% for Q2FY26. PBT: Rs 129.0 crore compared to Rs 48.5 crore during Q2FY25, change 166.60%. PAT: Rs 96.5 crore compared to Rs 32.0 crore during Q2FY25, change 201.60%. Sucheth Davuluri, Vice-Chairman & Chief Executive Officer, said: “The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.” Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.” Result PDF